Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,700+ customers and partners access the world’s most-used platform for clinical development, commercial, and real-world data.
VivoSense is the world leader in data analysis consulting and software, specializing in wearable sensor physiological monitoring solutions for clinical trials, healthcare research, and consumer wellness. VivoSense develops regulatory compliant digital biomarkers using the data from wearable sensors.
Loss of mobility is a growing unmet need. FeetMe for the first time in the world will be the trustworthy partner for mobility specialists and patients to improve mobility with smart active wearables and collect key objective information to make life impacting therapeutic decisions.
NeuraMetrix TC (Typing Cadence) is a digital brain health biomarker platform measuring typing inconsistency. We monitor brain health without any tests or special equipment. Installed on a personal computer, it captures typing cadence in milliseconds, allowing the detection of subtle changes in cognitive and motor function and calculation of a digital biomarker.
The Digital Biomarkers & Digital Measurements Summit is back with a bang! Bringing you 2 full days of cutting-edge content and an industry leading speaker faculty, this event provides you with a one-stop shop of all things digital biomarkers & digital measurements ensuring you leave the event with key takeaways and the knowledge to accelerate your own digital journey. We’ve got a lot to catch up on and this Summit has got you covered!
Starting with the differences between digital biomarkers, measurements and endpoints, through to commercialization, this Summit will provide you with a truly end-to-end learning experience. Learning is at the heart of the agenda and through a variety of dynamic formats, you will be able to accelerate your understanding of the industry in just two days.
Digital biomarkers and digital measurements have long been explored but with the recent changes to healthcare and pharma, there is greater interest than ever before in what they can offer. This Summit will help define this new wave of the industry through exclusive discussions with the movers and shakers, and this is your chance to be part of them.
The COVID-19 public health emergency shifted a number of protocols and operating plans for clinical research and care alike. As more trials and care shift to the home, convening folks working on these problems in a common summit will help us ensure that more high quality measures support patients at home.
Digital Biomarkers & Digital Measurements Summit is ideally timed to enable critical conversations between stakeholders enabling the progression of medicine toward a patient-oriented, decentralized, tech-enabled future.
Continuing the conversation from last year, the Digital Biomarkers & Digital Measurement Summit is once again providing the platform to bring together key stakeholders who are driving digital innovation within healthcare. I’m excited to learn from leaders in the space and collaboratively advance this exciting field.
The Digital Biomarkers event is a critical place to learn, evaluate, and “take inventory” in an industry that is the front door to enabling the promise of precision medicine. I’m particularly intrigued to learn about how innovators are thinking about the validation of digital biomarkers to be used as clinical endpoints, then how they can be embedded into digital therapeutics for real-world use.
2021 Speaker Faculty
Dr Karlin is the CEO and the co-founder at HealthMode.com. He was previously the Head of Clinical, Informatics, and Regulatory Strategy for Digital Medicine at Pfizer, having passed through a number of roles on the way to this position including Senior Director, Quantitative Medicine, Group Lead for Human Biology and Medical Informatics with Pfizer’s Neuroscience Research Unit in Cambridge, MA. He is an Assistant Professor at Tufts Medical Center in Boston, and had been the Director of Psychiatry Informatics, and the Associate Training Director for Psychiatry. His primary research interests are neuropsychiatric drug development, medical informatics, cognition in clinical medicine, and methods for medical education, especially as these relate to decision-making strategies used by medical professionals. In addition, Dr Karlin is actively involved in designing and implementing information systems and resources for clinical and research use. Dr Karlin trained in Psychiatry at Tufts Medical Center, attended medical school at the University of Colorado School of Medicine, and graduate school for Clinical Informatics and Cognitive Science as well as undergraduate studies in Neuroscience and Behavior at Columbia University. He is board certified in Psychiatry, Addiction Medicine, and Clinical Informatics.
Jennifer C. Goldsack co-founded and serves as the Executive Director of the Digital Medicine Society (DiMe), a 501(c)(3) non-profit organization dedicated to advancing digital medicine to optimize human health. Jen’s research focuses on applied approaches to the safe, effective, and equitable use of digital technologies to improve health, healthcare, and health research. She is a member of the Roundtable on Genomics and Precision Health at the National Academies of Science, Engineering and Medicine.
Previously, Jen spent several years at the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by Duke University and the FDA. There, she led development and implementation of several projects within CTTI’s Digital Program and was the operational co-lead on the first randomized clinical trial using FDA’s Sentinel System.
Jen spent five years working in research at the Hospital of the University of Pennsylvania, first in Outcomes Research in the Department of Surgery and later in the Department of Medicine. More recently, she helped launch the Value Institute, a pragmatic research and innovation center embedded in a large academic medical center in Delaware.
Jen earned her master’s degree in chemistry from the University of Oxford, England, her masters in the history and sociology of medicine from the University of Pennsylvania, and her MBA from the George Washington University. Additionally, she is a certified Lean Six Sigma Green Belt and a Certified Professional in Healthcare Quality. Ms Goldsack is a retired athlete, formerly a Pan American Games Champion, Olympian, and World Championship silver medalist.
With over a decade of experience in both academic and clinical research, Nathan develops scientifically valid and clinically sensitive digital solutions for measuring cognitive performance in health care and clinical trial research environments. Over the past 15 years, Nathan has had a breadth of Cognitive Neuroscience research experience using a synergy of novel methodology and clinical populations, across multiple institutions in North America, Europe and the United Kingdom. His experience ranges from establishing in vivo bio-markers to track disease progression, to creating computational modeling approaches characterizing human cognitive processes and even performing functional neuroimaging on California Sea Lions suffering from neurological damage. With this advanced insight into brain/behavior relationships, Nathan now provides comprehensive scientific consultancy and potentiates the development of digital innovations for clinical trial experimentation in order to optimize design, outcome and ultimately to help those in need.
Ben Schlatka joined Medidata in 2020 through Medidata’s acquisition of MC10’s Digital Biomarker Business. After beginning his career as a corporate “intraprenuer” at IBM, Ben grew a series of successful startups including including Volunteer Solutions.org (Sold to the United Way) and Nantero (Sold to Lockheed Martin). Most recently, Ben Schlatka was co-founder & CEO of MC10, a pioneer in sensors and new end point development in clinical research. Ben is passionate about using digital technologies to transform the lives of patients, in both clinical research and clinical practice. He holds an MBA from the Harvard Business School and frequently lectures on the formation of disruptive science based businesses.
Andy Coravos (@andreacoravos) is the CEO/co-founder of HumanFirst FKA Elektra Labs, building a digital medicine platform focusing on digital biomarkers for decentralized clinical trials. Formerly, she served as an Entrepreneur in Residence at the FDA working in the Digital Health Unit (DHU). She serves on the Board of the Digital Medicine Society (DiMe), and she’s an advisor to the Biohacking Village at DEF CON.
Christine Guo leads ActiGraph’s clinical and data science team. She has over 15 years of clinical research experience and a passion for leveraging data and technology to improve people’s health. Prior to ActiGraph, Christine was Head of Scientific Innovation at Biogen Healthcare Solutions, leading the clinical development and validation of digital medicine products in multiple sclerosis, neuromuscular and neurodegenerative diseases.
Christine is Head of Applied Sciences at HumanFirst FKA Elektra Labs, leading the development of the Atlas platform to facilitate measurement selection and technology evaluation and deployment for remote monitoring in research and clinical care. She currently serves as a Research Lead the Digital Medicine Society (DiMe) supporting projects on meaningful measurement selection and evidence quality. Prior to joining HumanFirst Christine supported the Clinical Trials Transformation Initiative (CTTI)’s systematic review of feasibility studies using mobile technologies in clinical research. She has six years of experience working in research at academic institutions and hospital systems including Christiana Care’s Value Institute, University of Pittsburgh Medical Center (UPMC) and Children’s Hospital of Philadelphia (CHOP).
Joss is a technologist with extensive marketing experience, demonstrated by his track-record developing new ventures, products and services. He has created product pipelines and long-term technology portfolios for branded consumer goods, while also running significant product development programmes.
He has built global professional consulting services and had work recognised through design awards, academic papers and filed numerous patents in a range of technical disciplines. In recent years, Joss has developed global standards for the management of personal data.
Kate Lyden, Ph.D. Chief Science Officer for VivoSense, Kate has an extensive and diverse background in the development and implementation of wearable sensor methodologies across clinical, academic, and industry settings. She is passionate about leveraging the power of connected sensor technologies to gain meaningful insights into real-world patient behaviors and experiences.
Peter R. Bergethon, M.D. is Vice President and Head of Digital and Quantitative Medicine (DQM) at Biogen. He leads the identification of technologies and methodologies that transform drug development. DQM creates value by leading the transition of clinical practice in Biogen’s core and emerging growth areas from a qualitative to a quantitative discipline, and connecting the Clinical with the Research enterprise, to advance therapeutics and personalized medicine.
Peter came to Biogen in 2017 from Pfizer Worldwide Research and Development where he was Vice President and Head of the Pfizer Innovation Research Lab within the Early Clinical Development group. At Pfizer, Peter led both the Quantitative Medicine group and the Innovation Research Labs where he pioneered mobile and digital clinical assessment technology, human neurophenotyping, and multi-modal data analytics to accelerate clinical development in neuroscience, immunology, rare diseases, and cardiometabolic disease.
He is an accomplished clinical neurologist and neuroscientist who, prior to joining Pfizer, was a Professor at Boston University and Tufts University in the Departments of Biochemistry, Neurology, Neurobiology & Anatomy, and Biomedical Engineering.
Vaibhav is currently Vice President and Head of Data Science for the Neuroscience Therapeutic Area. In this role, Vaibhav is responsible for applying advanced analytics to genetic, molecular, clinical and digital phenotyping data to gain disease insights, discover novel drug targets and enable precision and predictive medicine strategies in Neuroscience. Vaibhav has pioneered use of data derived from wearable sensors and smartphones to develop digital biomarkers for early detection, disease progression, drug response, treatment monitoring and relapse prediction in Alzheimer’s, Mood and Schizophrenia.
Vaibhav joined Johnson and Johnson from Eli Lilly and Co., where he was the Head of Discovery and Medical Informatics group. Prior to Lilly, Vaibhav held multiple leadership roles in bioinformatics and genomics start-up companies, including Celera Genomics where he participated in the sequencing, assembly and analysis of the human genome.
Vaibhav obtained his PhD from Yale University in Computational Biology in 1998 and an Executive MBA from Kellogg School of Management, Northwestern University in 2009.
Jessica Robin is the Director of Clinical Research at Winterlight Labs, leading the research and development of speech-based digital measures. Jessica has a PhD in cognitive neuroscience from the University of Toronto, and over ten years experience conducting behavioural and neuroscientific research on topics including cognition, neurodegenerative disease and psycholinguistics.
Dr. Jessilyn Dunn is an Assistant Professor of Biomedical Engineering and Biostatistics & Bioinformatics at Duke University. Her primary areas of research focus on biomedical data science and mobile health; her work includes multi-omics, wearable sensor, and electronic health records integration and digital biomarker discovery. Dr. Dunn is the Director of the BIG IDEAs Laboratory, whose goal is to detect, treat, and prevent chronic and acute diseases through digital health innovation. She is also currently PI of the CovIdentify study to detect and monitor COVID-19 using mobile health technologies. Dr. Dunn was an NIH Big Data to Knowledge (BD2K) Postdoctoral Fellow at Stanford and an NSF Graduate Research Fellow at Georgia Tech and Emory, as well as a visiting scholar at the US Centers for Disease Control and Prevention and the National Cardiovascular Research Institute in Madrid, Spain. Her work has been internationally recognized with media coverage from the NIH Director’s Blog to Wired, Time, and US News and World Report.
Tom is a Digital Health Scientist in Genentech’s Research and Early Development Informatics Digital Transformation Office (gRED DTO). His current focus is on developing a digital health technology strategy focusing on supporting technology and endpoint development deployment across the Genentech early development portfolio. Tom has over 20 years of clinical development experience, including 8 years of experience in developing and deploying digital technologies in clinical trials. He has been at Genentech since 2010 serving in a variety of roles within Clinical Operations, Innovation, and Digital Health. An exercise physiologist by training and an avid bicycle racer since he was 16, he has been continuously tinkering with the various digital gadgets on himself before testing them on other people. He lives in San Mateo, CA with his wife Elizabeth and 4 young children.
Siavash Sarlati is a medical director at Anthem Digital. He is a practicing emergency physician and brings expertise in health disparities, populations with complex psychosocial needs, evidence-based medicine, and their intersections with health IT to Anthem’s digital health initiatives. Siavash has spent his first year at Anthem focused heavily on developing and launching the Asthma Digital Study to investigate, in partnership with Apple Inc. and the University of California-Irvine, the impact of a consumer-grade sensor platform on the success of adult asthma self-management. This is a first-of-its-kind, national, decentralized, digital study to be sponsored by Anthem. Prior to joining Anthem, Siavash was a full-time clinician in safety-net hospitals and explored how tech-enabled solutions can help emergency departments and acute care centers support patients with complex psychosocial needs.
Yvonne Chan, MD, PhD, FACEP is a physician executive, board certified Emergency
physician, digital health researcher and strategist. She has broad experience in healthcare,
clinical research, and digital health with a focus on personalized medicine and collaborations.
Dr. Chan is dedicated to developing and driving groundbreaking digital programs and products
in industry and academia to deliver real-world impact for patients from diverse backgrounds.
She is the Founder and CEO of Agile Science Consulting LLC.
Previously, Dr. Chan was the Founding Director of the Center for Digital Health at the Icahn
School of Medicine at Mount Sinai in NYC. The mission of her Digital Health Center was to drive
large-scale patient participation in biomedical research and clinical care, by leveraging the latest
digital technology and advanced analytic techniques to uncover novel insights and actionable
results. She was also the Senior Director for Digital Medicine at Otsuka Pharmaceuticals. She
served as the clinical expert of cross-functional teams to develop advanced methodologies and
tech platforms for medical adherence, virtual care and clinical decision support as well as derive
real-world clinical evidence.
Dr. Chan is the executive in residence and a Scientific Leadership Board member of the Digital
Medicine (DiMe) Society. She is also an editorial board member of Nature Partner Journals (npj)
Digital Medicine and Digital Biomarker Journals.
Liam Kaufman is the CEO and cofounder of WinterLight Labs, which develops digital biomarkers to quantify cognitive impairment and mental health using speech and machine learning. Liam has authored multiple peer-reviewed scientific publications in neuroscience, cognitive neurology and human-computer interaction.
Rebecca Kirch is EVP of Policy and Programs for the National Patient Advocate Foundation (NPAF) based in Washington, DC. In this role, she provides strategic focus and leadership in bringing patient and caregiver voices and values to the forefront of health reform efforts through influential advocacy and grassroots mobilization. As a leading health policy expert and advocate in her field, Rebecca is dedicated to advancing person-centered policies and practices that put people at the heart of healthcare.
Prior to joining NPAF in 2016, she served for 15 years with the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network, directing development and execution of coordinated quality of life and survivorship research, policy and advocacy activities.
A frequently invited speaker on patient and family engagement about person-centered care priorities and practices, Rebecca has authored numerous articles and book chapters, including publications in the New England Journal of Medicine, Archives of Internal Medicine, Health Equity, JAMA Oncology, Health Affairs, Circulation and other professional journals. She is the recipient of numerous national awards, has been featured in multiple media outlets and also serves on National Quality Forum’s MAP Coordinating Committee and Consensus Standards Approval Committee and ICER’s New England Comparative Effectiveness Public Advisory Council.
Among other advisory committees and advocacy coalitions, Rebecca is currently an active participant of the National Academy of Science, Engineering and Medicine’s Quality Care for People with Serious Illness Roundtable, co-chair of the Quality of Life and Person-Centered Care task force for the American Congress of Rehabilitation Medicine and a board member for children’s oncology Care Camps.
Beau Woods is a Cyber Safety Innovation Fellow with the Atlantic Council, a leader with the I Am The Cavalry grassroots initiative, Founder/CEO of Stratigos Security, and sits on the board of several non-profits. His work bridges the gap between the security research and public policy communities, to ensure connected technology that can impact life and safety is worthy of our trust. He formerly served as Entrepreneur in Residence with the US FDA, and Managing Principal Consultant at Dell SecureWorks. Over the past several years in this capacity, he has consulted with the energy, healthcare, automotive, aviation, rail, and IoT industries, as well as cyber security researchers, US and international policy makers, and the White House. Beau is a published author, frequent public speaker, often quoted in media, and is often engaged for public or private speaking venues.
Carrie Northcott, PhD is a Director/ Project Lead within Digital Medicine and Translational Imaging (DMTI), Early Clinical Development (ECD) at Pfizer. She leads a driven and diverse team that is evaluating and validating the use of wearable digital devices to more fully understand and characterize physiological endpoints, such as quantitatively measuring night-time scratch and sleep. Carrie has a diverse scientific background in Pharmacology, Toxicology, and Physiology which provides unique insight into understanding how these novel digital endpoints provide meaningful information to patients, doctors and researchers to better treat and understand diseases.
Ariel Dowling, PhD is a Director of Digital Strategy within the Data Sciences Institute at Takeda Pharmaceuticals. In this role, Ariel oversees the strategy, assessment, and deployment of digital devices in clinical studies across the organization. She was previously a Senior Clinical Data Scientist at Biogen, the algorithm team lead at MC10, and a senior research scientist at BioSensics. Ariel holds an MS and PhD in Mechanical Engineering from Stanford University and a BE from Dartmouth College. She serves on the Strategic Advisory Board of the DiMe Society.
Clemens Becker is a Professor of Digital Geriatric Medicine at the University of Heidelberg and is the Clinical Lead of the Mobilised-D Clinical Validation Study at Stuttgart. Professor Becker received his MD from the University of Giessen, Doctoral thesis from the University of Heidelberg and Postdoctoral qualification (Habilitation) from Ulm University.
Among others, some of Professor Beckers major research grants include Prevention and Rehabilitation of Osteoporotic Fractures in Persons with Disadvantages 2 (2011-2019), Early risk detection and prevention in ageing people by self-administered ICT-supported assessment and a behavioural change intervention delivered by use of smartphones and smartwatches (PreventIT) (2015-2017), Comparison of a Group-delivered and Individually Delivered Lifestyle-integrated Functional Exercise (LiFE) Program in Older Persons (LiFE-is-LiFE) (2017-2021) and most recently, Mobilise-D, Validation of Digital Mobility Outcomes, IMI European Commission (2019-2024).
Dr Chris Richter is a biomechanist with extensive experience in data science and technology. Chris is currently working on developing and implementing a biomarker R&D strategy to fully utilize Kaia’s computer vision movement capture technology, which is used to guide remote rehabilitation.
For the last 10 years, Chris has been involved in clinical and research projects as Head of Data Analytics and Innovation at the Sports Surgery Clinic in Dublin. During this time, Chris has contributed to / published 60+ papers and has been acting as reviewer for 15+ scientific journals. In addition to the scientific work, Chris has also tackled many questions in respect to movement analysis in professional sports for various NBA and Premier League teams.
Dr. Ghaffari graduated from MIT with BS and MEng degrees in Electrical Engineering and received his PhD in biomedical engineering from the Harvard-MIT Division of Health Sciences and Technology. Dr. Ghaffari is currently Director of Translational Research at Northwestern University’s Querrey Simpson Institute for Bioelectronics and is Research Associate Professor in the Department of Biomedical Engineering. In 2017, Dr. Ghaffari co-founded and has served as CEO of Epicore Biosystems, a health solutions company commercializing ambulatory wearable microfluidic devices for tracking health and hydration biomarkers. Prior to Epicore Biosystems, Dr. Ghaffari co-founded and served as CTO of wearable health technology company, MC10, where he led the development and launch of the BioStamp Wearable System for tracking movement disorders in remote clinical trials. His contributions in soft bioelectronics, biosensors, microfluidics and neuroscience have been recognized with the MIT100K Grand Prize, IEEE Spectrum Emerging Technology Prize, and the MIT Technology Review Magazine’s Top 35 Innovators Under 35. He has published over 90 academic papers and is inventor on over 50 patents issued.
Dr. Kate Papp is an Assistant Professor of Neurology at Harvard Medical School. She works as a Clinical Neuropsychologist in the Department of Neurology at the Brigham and Women’s Hospital and the Massachusetts General Hospital. She serves as the Lead Neuropsychologist and the Co-Leader of the Outcomes Core for the Alzheimer’s Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER). She is a member of the Cognitive Outcome Instrument Unit of the Alzheimer’s Clinical Trial Consortium (ACTC). She is an investigator in the Clinical Core of the Harvard Aging Brain Study, a longitudinal cohort study of normal older adults with annual cognitive testing in addition to multimodal imaging (including amyloid and tau PET).
She has worked in the development and validation of digital measures of cognitive performance for the preclinical Alzheimer’s disease population including implementing computerized testing using the C3 in Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (A4). She more recently received a Pilot Award Grant from the Massachusetts Alzheimer’s Disease Research Center to further develop the mobile-based testing of memory with the Boston Remote Assessment for Neurocognitive Health (BRANCH). She is funded by the National Institute on Aging and the Alzheimer’s Association.
Robert Goldel is a founder, neuroscientist, and data-driven technologist. His research has applied behavioral and neuroimaging methods to analyze core brain functions, including memory, learning, attention, and decision making. At Neumitra, his team launched the first smart watch to measure and manage the physiology of the autonomic nervous system with real-time biofeedback and self-learning software. Working with designers, engineers, and researchers, their technologies applied continuous biosensor data to personalize devices and software with statistical learning on mobile phones and backed by cloud-based analytics. Their software and algorithms showed how artificial intelligence can respond with empathy to manage brain health and cognitive functions across daily life demands for diverse populations.
Robert’s work has been supported by the National Science Foundation, the National Institutes of Health, Breakout Labs at the Thiel Foundation, the Defense Advanced Research Projects Agency, the Robert Wood Johnson Foundation, and the founders and innovators of Boston Scientific, General Magic, iRobot, SmartCells, and Yahoo. His research and technologies have focused on applying continuous data streams to new types of software and user experiences for better understanding the human brain. As a Rock Health and MassChallenge alumnus, Robert has been inspired by efforts that catalyze ecosystems and infrastructures to build, grow, and sustain organizations for impacts and the people behind them. He is passionate about answering questions in daily brain functions, as for knowledge workers, families, enterprises, national defense, and social impacts towards advancing educational metrics, improving health, optimizing productivity, and increasing life expectancy.
Ida Sim, MD, PhD is Professor of Medicine at the University of California, San Francisco, where she co-directs Informatics and Research Innovation at UCSF’s Clinical and Translational Sciences Institute, and is Director of Digital Health for the Division of General Internal Medicine. Dr. Sim’s research focuses on open integrated architectures of mobile technologies for clinical research and primary care. She is a global leader in the policy and technology of large-scale sharing of clinical trials and mobile health data. In 2011, she co-founded Open mHealth, a non-profit organization that is breaking down barriers to mobile health app and data integration through an open software architecture. In 2017, she co-founded Vivli, a global data sharing platform for finding, requesting, and analyzing participant-level clinical trials data. Her digital health projects include integrating patient-reported outcomes into primary care, management of hypertension and depression in primary care, N-of-1 studies on wellbeing and chronic pain management, analytic platforms for real-time mobile data provenance and analysis, and cloud infrastructure for patient-generated data.
Dr. Sim has served on multiple advisory committees on health information infrastructure for clinical care and research, including committees of the National Research Council and National Academy of Medicine. She is a recipient of the United States Presidential Early Career Award for Scientists and Engineers (PECASE), a Fellow of the American College of Medical Informatics, a member of the American Society for Clinical Investigation, and is a practicing primary care physician.
Mette Dyhrberg is the founder and CEO of Mymee. An economist turned diagnostician. She conceived of Mymee after years of being treated by a healthcare system that did not know how to effectively identify and manage autoimmune diseases. From the very beginning, she believed that decoding the body’s hidden patterns would lead to a truly personalized approach to disease management. As an authority on autoimmune issues, Mette speaks regularly on how to reinvent healthcare.
Owen McCarthy is the President and co-founder of MedRhythms, a digital therapeutics company that uses sensors, music, and software to build evidence-based, neurologic interventions to measure and improve walking. Owen is passionate about solving problems, seeking out challenges, and helping people. Owen has become a leader in the field of digital therapeutics. He serves on the board of directors of the Digital Therapeutics Alliance, the industry trade association for the DTx industry. Since founding MedRhythms in 2016, Owen has been invited to speak at digital therapeutics conferences and events across the country, including DTx West, DTx East, Ipsos, Clinically Validated DTx conference, Neurotech Investing and Partnering Conference, Partners Connected Health Conference, and HLTH Evercore ISI Panel.
Melinda Decker is Chief Commercial Officer of Mymee, Inc., a digital health company that empowers those who suffer from autoimmune disease to reclaim their health. She is also a digital health advisor to several companies, including in the area of digital biomarkers. Melinda also serves as an advisor to MIT’s Health Science & Technology program and to Plexus Ventures, a global business development firm. She previously held leadership roles at AstraZeneca and Pfizer, spanning commercial and R&D.
Shoibal is the Head of the Digital Strategy Group within the Data Sciences Institute at Takeda. In support of Takeda’s commitment to digital and data he is responsible for working with colleagues across the enterprise to develop patient-centric digital strategies for the development of novel endpoints, make studies more resilient through decentralized approaches and help bring innovations in digital health from R&D through to commercial.
Prior to this Shoibal was Vice President of PPD Digital where he was responsible for setting the strategy and working with external platform partners and device manufacturers to devise compliant, globally scalable approaches to conduct decentralized trials and to oversee the integration of the technologies into conventional clinical research and data management processes. He also spent 13 years at Biogen in a range of roles in translational informatics, data sciences and as part of an innovation hub that launched MS PATHS, a learning healthcare system that utilises technology to capture high quality data as standard of care for over 10,000 MS patients globally supporting RWE and value-based medicine initiatives.
Aman Thukral is the head of Digital Operations and Clinical Systems at AbbVie. He has over fourteen years of experience in clinical development, technology planning & business-technology alignment. He is responsible for eCOA operations, wearables, and sensors and piloting new technology initiatives. Before this position, he had worked in Deloitte, Cognizant & GlaxoSmithKline at various levels
Benjamin Vandendriessche is Chief Medical Officer at Byteflies, the Belgian-American company behind Sensor Dot, a powerful platform for 24/7 capture of medical insights to deliver care at home and augment clinical trials with real-world data. He is specialized in molecular biology, systems physiology, and data analytics for physiologic waveform and vital sign processing. He completed a PhD in Molecular Biology at Ghent University as an IWT Fellow, followed by a postdoc in Computer Science at Case Western Reserve University (CWRU) as a BAEF Fellow. He currently is an adjunct assistant professor at CWRU.
Dr. Timothy Callahan, PhD is the VP of Scientific Affairs for BioTel Research. He brings over 30 years of clinical research expertise to the position; including conducting research in Silent Myocardial Ischemia at the National Institutes of Health in Bethesda, Maryland. An expert in diagnostic testing, Dr. Callahan co-authored 2 patents in QT interval analysis and a patent in dynamical systems modeling of ECG data. He has authored and co-authored many abstracts and publications as well as serving as the moderator for three FDA QT-IRT – ECG Core Lab meetings. Dr. Callahan has attended regulatory meetings and has assisted clients in preparing regulatory submissions.
He is a frequent speaker at Pharmaceutical Industry functions and sits on several advisory boards for peer reviewed publications, as well as cardiovascular safety committees for sponsors.
Krishna is a physician-scientist, business oriented R&D leader with a wealth of U.S. and global life science industry experience in Medical affairs, Clinical development, academic research, and pharmacovigilance across multiple therapeutic categories. A collaborative and outcomes oriented leader, Krishna’s efforts have contributed to revenue growth through innovation and pipeline development, Rx to OTC Switch, clinical trial design and execution, medical affairs, scientific engagement and stakeholder outreach. Krishna has also successfully managed several FDA and international health authority submissions.
Krishna currently serves as Senior Clinical Lead within the Motion Biosensors Group at Philips Healthcare with global responsibility for ensuring scientific accuracy and value in various external facing engagements, scientific strategy, innovation, clinical development, algorithm validation, FDA engagement and interactions, and streamlining several commercial and sales scientific initiatives. Prior to joining Philips HealthCare, Krishna served in various roles at Merck and Bayer including Global Medical Strategic Director for upper respiratory, switch categories, white space, and women’s health portfolio, Clinical Development lead, and Pharmacovigilance officer. Earlier in her career, Krishna was also a medical writer with Care Management International.
Krishna earned her PhD in neuropharmacology from Southern Illinois University School of Medicine in Carbondale. Prior to this, Krishna also earned her Doctor of Medicine (MD) degree in Family Medicine from Bombay University in India. She has held various research positions at the Johns Hopkins University and University of Virginia in areas of neurodegenerative disorders and cardiovascular research.
To provide you with the very best virtual experience, the Digital Biomarkers & Digital Measurements Summit will be hosted on Hopin, a world-class purpose-built platform for exceptional events.
The benefits of virtual are endless! For starters, no more wondering who is in the room! View and message the entire attendee list, or reach out to any attendee through their connected LinkedIn profiles. If that’s not enough, there are a multitude of structured and unstructured networking opportunities to give you the chance to reconnect with old friends and meet your future collaborators.
Then there’s the learning! Through an engaging and connected live agenda, you can interact directly with the speakers, through Q&A, polls, interactive panel discussions, and more. And with recordings available for six months post-event, you won’t miss out on any of the exclusive content, no matter your schedule.
Imagine the possibilities for networking and learning!
Partner with Us
The Digital Biomarkers & Digital Measurements Summit being online presents an opportunity for us to super-charge our offering. We have selected the best-in-class platform to offer our attendees a wide range of options to learn, network, and collaborate. The result, bringing together the senior R&D exec’s from across digital health, pharma, healthcare, investors and beyond.
Making your session engaging and knowledgeable will attract the largest audience. We will guide you on how best to maximize the benefits of using our platform.
No need to sit behind a desk! Our networking tools enable attendees to arrange 121 video conversations as well as taking part in curated networking sessions. You could potentially meet many more people than you would in a typical venue setting.
Get in touch to learn more about the options available at The Digital Biomarkers & Digital Measurements Summit.
Register for the Event
For pricing and booking options please click the button to go to the registration page.